Get started
Author

Meg Fay Mortman

Observed name: M.F. Mortman
Institution: Go2 for Lung Cancer
Observed institution: Go2 for Lung Cancer
ORCID: 0009-0003-5682-0083
Observed ORCID: 0009-0003-5682-0083
OpenAlex ID: A5120125091
P1.090: Monitoring Stage Shift in a National Network of Screening Programs: Successes and Challenges in Real-World Implementation
2026 · A.M. Barry, M.F. Mortman, et al. · Journal of Thoracic Oncology
P2.235: Real-World Assessment of Biomarker Testing Turn Around Time Impacts in US-Based Lung Cancer Treatment Programs
2026 · A. Ciupek, A. Barry, et al. · Journal of Thoracic Oncology
P3.404: Reality Check: Identifying Real-World Barriers to Clinical Trial Engagement
2026 · B.N. Nichols, A. Ciupek, et al. · Journal of Thoracic Oncology
P3.044: A Revealing Snapshot Into Implementation of Smoking Cessation Services Across Academic and Community-Based Facilities
2026 · J.T. Fathi, A. Ciupek, et al. · Journal of Thoracic Oncology
Evolving Lung Cancer Navigator Practice Through Targeted Professional Development
2026 · Sydney J. Lloyd, Meg Fay Mortman, et al. · CHEST Journal
PDF
Navigation in Lung Cancer Prevention, Detection, and Care
2025 · Meg Fay Mortman, Angela Gonnella, et al. · Springer eBooks
PDF
P3.16.22 Frontline Insights in US Payer Barriers Impacting Patient Access and Participation in Comprehensive Lung Cancer Screening Programs
2025 · A.M. Barry, M.F. Mortman, et al. · Journal of Thoracic Oncology
Works count: 7
Citation count:
H-index:
I10-index:
Year
Topic
Type